Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

被引：4

作者：

Thomas, Xavier ^{[1
]}

Elhamri, Mohamed ^{[1
]}

Deloire, Alexandre ^{[1
]}

Heiblig, Mael ^{[1
]}

机构：

[1] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Clin Hematol, Pierre Benite, France

来源：

EXPERT OPINION ON EMERGING DRUGS | 2022年 / 27卷 / 02期

关键词：

Acute myeloid leukemia; monoclonal antibodies; drug conjugate antibodies; unconjugated antibodies; bi-specific recombinant antibodies; radio-conjugated antibodies; CAR-T cells; immune checkpoint treatments; ANTI-CD33; MONOCLONAL-ANTIBODY; ACUTE MYELOGENOUS LEUKEMIA; EVENT-FREE SURVIVAL; CAR T-CELLS; GEMTUZUMAB OZOGAMICIN; OLDER PATIENTS; ADULT PATIENTS; AMG; 330; INDUCTION CHEMOTHERAPY; PARTICLE IMMUNOTHERAPY;

D O I：

10.1080/14728214.2022.2094365

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk profile, and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. Areas covered: The current paper reviews the clinical development of monoclonal antibody-based therapies in AML, their current status and phases 2 and 3 prospective trials. Expert opinion: Monoclonal antibody-based therapies demonstrated efficacy and tolerability in several clinical trials, especially when used in combination either with '3 + 7' chemotherapy or with low-intensity treatments. Additional studies are needed to determine new antigens for antibody-based therapies that target leukemia stem cells and spare normal hematopoiesis. Phase 2 and 3 additional clinical trial data are needed to assess the promise of first trials, especially regarding chimeric antigen receptor T cells redirected against myeloid antigens and immune checkpoint inhibitor therapies.

引用

页码：169 / 185

页数：17

共 143 条

[1] Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia [J].

Aldoss, Ibrahim ;

Uy, Geoffrey L. ;

Vey, Norbert ;

Emadi, Ashkan ;

Sayre, Peter H. ;

Walter, Roland B. ;

Foster, Matthew C. ;

Arellano, Martha L. ;

Godwin, John E. ;

Wieduwilt, Matthew J. ;

Byrne, Michael T. ;

Michaelis, Laura C. ;

Stiff, Patrick J. ;

Carrabba, Matteo Giovanni ;

Chevalier, Patrice ;

Gyan, Emmanuel ;

Recher, Christian ;

Advani, Anjali S. ;

Wermke, Martin ;

Erba, Harry P. ;

Ciceri, Fabio ;

Huls, Geert ;

Jongen-Lavrencic, Mojca ;

Topp, Max S. ;

Curti, Antonio ;

Ravandi, Farhad ;

Rettig, Michael P. ;

Muth, John ;

Collins, Mary Beth ;

Timmeny, Erin ;

Guo, Kuo ;

Zhao, Jian ;

Tran, Kathy ;

Kaminker, Patrick ;

Patel, Priyanka ;

Bakkacha, Ouiam ;

Curtis, Teia ;

Jacobs, Kenneth ;

Kostova, Maya ;

Seiler, Jennifer ;

Lowenberg, Bob ;

Rutella, Sergio ;

Bonvini, Ezio ;

Davidson-Moncada, Jan K. ;

DiPersio, John F. .

BLOOD, 2020, 136

[2] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[3] Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17) [J].

Amadori, Sergio ;

Suciu, Stefan ;

Stasi, Roberto ;

Salih, Helmut R. ;

Selleslag, Dominik ;

Muus, Petra ;

De Fabritiis, Paolo ;

Venditti, Adriano ;

Ho, Anthony D. ;

Luebbert, Michael ;

Thomas, Xavier ;

Latagliata, Roberto ;

Halkes, Constantijn J. M. ;

Falzetti, Franca ;

Magro, Domenico ;

Guimaraes, Jose E. ;

Berneman, Zwi ;

Specchia, Giorgina ;

Karrasch, Matthias ;

Fazi, Paola ;

Vignetti, Marco ;

Willemze, Roel ;

de Witte, Theo ;

Marie, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) :4424-+

[4] Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19) [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Stasi, Roberto ;

Alimena, Giuliana ;

Baila, Liliana ;

Rizzoli, Vittorio ;

Borlenghi, Erika ;

Gaidano, Gianluca ;

Magro, Domenico ;

Torelli, Giuseppe ;

Muus, Petra ;

Venditti, Adriano ;

Cacciola, Emma ;

Lauria, Francesco ;

Vignetti, Marco ;

de Witte, Theo .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) :376-382

[5] Gemtuzumab ozogamicin for acute myeloid leukemia [J].

Appelbaum, Frederick R. ;

Bernstein, Irwin D. .

BLOOD, 2017, 130 (22) :2373-2376

[6] C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia [J].

Bakker, ABH ;

van den Oudenrijn, S ;

Bakker, AQ ;

Feller, N ;

van Meijer, M ;

Bia, JA ;

Jongeneelen, MAC ;

Visser, TJ ;

Bijl, N ;

Geuijen, CAW ;

Marissen, WE ;

Radosevic, K ;

Throsby, M ;

Schuurhuis, GJ ;

Ossenkoppele, GJ ;

de Kruif, J ;

Goudsmit, J ;

Kiuisbeek, AM .

CANCER RESEARCH, 2004, 64 (22) :8443-8450

[7] Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT [J].

Battipaglia, G. ;

Labopin, M. ;

Candoni, A. ;

Fanin, R. ;

El Cheikh, J. ;

Blaise, D. ;

Michallet, M. ;

Ruggeri, A. ;

Contentin, N. ;

Ribera, J. M. ;

Stadler, M. ;

Sierra, J. ;

Borne, P. A. von Dem ;

Bloor, A. ;

Socie, G. ;

Nagler, A. ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2017, 52 (04) :592-599

[8]

Becker PS, 2014, BLOOD, V124

[9] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[10] Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies [J].

Borot, Florence ;

Wang, Hui ;

Ma, Yan ;

Jafarov, Toghrul ;

Raza, Azra ;

Ali, Abdullah Mahmood ;

Mukherjee, Siddhartha .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (24) :11978-11987

← 1 2 3 4 5 6 7 8 9 10 →